Advanced Radiation Therapy Improves Survival for Large Bile Duct Tumors

Researchers at The University of Texas MD Anderson Cancer Center have uncovered promising results for the treatment of large bile duct tumors in the liver through a specialized form of high-dose radiation therapy. The study, which was published in Clinical Cancer Research, demonstrates the potential of this approach to significantly enhance survival rates for patients with intrahepatic cholangiocarcinoma, a challenging form of liver cancer.

The study, led by Ethan Ludmir, MD, and Eugene Koay, MD, PhD, has shown that patients treated with an advanced radiation technique survived more than twice as long as those receiving chemotherapy alone. "Traditionally, such large tumors were not treated with radiation due to safety concerns," stated Ludmir. He emphasized that advancements in precision radiation delivery have made it feasible to safely target these tumors, thus significantly benefiting patient outcomes.

Intrahepatic cholangiocarcinoma can form exceptionally large tumors, often surpassing 10 centimeters. Previously, the risks associated with delivering sufficient radiation to these massive tumors without damaging nearby healthy liver tissue and other critical organs posed a significant barrier. However, MD Anderson’s radiation oncology team can now administer an ablative dose of radiation, effectively targeting the tumor while minimizing harm to surrounding tissues.

"This research challenges the notion that the size of intrahepatic cholangiocarcinoma tumors should limit the use of radiation therapy," remarked Koay. "Our findings indicate that these large tumors are not biologically distinct from smaller ones, suggesting that they respond similarly to high-dose radiation."

The retrospective study analyzed data from 34 patients treated with this targeted radiation therapy alongside chemotherapy, revealing a median overall survival of 28.7 months compared to 11.9 months for 29 patients who received only chemotherapy. Moreover, the combination treatment led to lower rates of tumor-related liver failure.

Remarkably, the therapy was well-tolerated among participants. There were no severe adverse effects, and only manageable occurrences of grade 3 radiation-induced liver disease and gastrointestinal issues were reported.

The research, initially spearheaded by Abi Jaoude, MD, reinforces the safety and efficacy of high-dose radiation therapy for large bile duct tumors. The study received funding from the National Institutes of Health and represents a significant step forward in offering viable treatment options for patients previously limited by the challenges presented by tumor size.